August 21, 2018
…. Although the gothic novella is far less fun when markets act like it’s their blueprint. Sector stocks have lately been alternating between the dreaded and the benign!
Out and about: Organogenesis, (potential symbol: ORGO) a wound care and skin graft biotech is going public again is merging with a special vehicle created by Avista Capital which will invest 92M. Organogenesis had gone private (2002) amid financial difficulties
Spare the SELL call, ruin the portfolio – SUBSCRIBE!
August 17, 2018
I maintain as a short-term trading vehicle as there is more historical upside to “eat” through!
Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates;
.... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%)
August 20, 2018
I answer one question, in which company should investors put, keep and commit their money!
Re-framing the main takeaway … pricing, volume and volatility as “our” universe suffers from “tourist” investing.
August 17, 2018
I maintain as a short-term trading vehicle as there is more historical upside to “eat” through! Rebounding CRSP (+$2.94 or +6.25%), EDIT (+$0.87 or +2.99%) and NTLA (+$1.02 or +3.78%) are candidates; .... after Wednesday’s CRSP (-$0.80 or -1.67%), EDIT (-$0.53 or -1.79%) and NTLA (-$0.92 or -3.30%)
August 16, 2018
Indication intelligence collects and analyzes sector information to sort-out weaknesses, vulnerabilities and strengths I know you have seen, read and appreciate RMi’s interpretation and sometimes clarification of news, perception and actionable intelligence including a pricing metric. I make a commitment to provide need-to-know “facts in evidence” with first, fast, and furious editions of what’s happening in the cell and gene therapy, immune-oncology and regenerative medicine sector even as or before news unfolds! Now I’m asking you to commit: http://www.regmedinvestors.com/create-account
August 15, 2018
Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies Thirty-five (35) LPS, four (4) net income and two (2) delayed or incomplete - Intrexon (XON) and MiMedx (MDXG) ... so far of 45 covered companies; The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.